Scientists discover new class of antiviral drugs against Covid infection
In a study published in the journal Nature, the researchers show that SARS-CoV-2 — the virus that causes COVID-19 — activates a pathway in cells that stops the production of peroxisomes and interferon, both key parts of the normal immune response.
The team from the University of Alberta in Canada successfully tested the new class of antiviral drugs that stimulate interferon production to reverse that effect.
Interferon stops infected cells from producing more virus by shutting down the infected cell, which often results in cell death, and then acts on the surrounding cells to prevent them from being infected, the researchers said.
The study builds on the team’s earlier research that showed how HIV has evolved to activate the Wnt/β-catenin signaling pathway in cells as a way to stop the body from producing peroxisomes, which trigger interferon production.
The team tried 40 existing drugs that target the Wnt/β-catenin signaling pathway. Most were originally developed and tested for treating cancer, which often responds to boosted interferon production.
Three of the drugs significantly reduced the amount of virus found in the lungs, and one of the drugs was also effective at reducing inflammation and other clinical symptoms in mice.
‘We saw, in some cases, a 10,000-fold reduction in the amount of virus produced in a test tube, and when we went into a mouse model, the drugs prevented severe weight loss and the mice recovered much quicker,’ said study lead author Tom Hobman, a professor at the University of Alberta.
During a viral outbreak, people who might have been exposed or who have already developed early symptoms would take a four- or five-day course to prime their peroxisome levels and limit the severity and spread of the disease.
‘The beauty of this approach is that in the absence of viral infection, there’s no interferon produced. We see these drugs potentially serving as first-line drugs against emerging viruses,’ Hobman added.
